Research desks at Zee Business and 3 other desks backed 5 stocks for short-term gains over the coming weeks, reflecting a broadly bullish market view.
Zee Business and 3 other registered desks issued 14 equity short term recommendations today, targeting gains over a 2 to 4 week horizon. The batch carries a bullish bias — 14 buys against 0 sells — covering 5 stocks.
ALKEM attracted 2 separate recommendations from registered analysts — Zee Business issued a buy at ₹5,574 targeting ₹5,790; Zee Business issued a buy at ₹5,613 targeting ₹5,790.
RADICO was flagged for a buy by Cnbc Awaaz at ₹152, targeting ₹155 — a potential upside of +2.0%, with a stoploss at ₹105. The risk-to-reward ratio stands at 1:0.1.
ABCAPITAL attracted 4 separate recommendations from registered analysts — Sislofficial issued a buy at ₹406 targeting ₹411 (stop ₹399); Sislofficial issued a buy at ₹406 targeting ₹414 (stop ₹399); Sislofficial issued a buy at ₹406 targeting ₹418 (stop ₹399); Zee Business issued a buy at ₹403 targeting ₹419 (stop ₹387).
Also covered: ARTEMISMED (₹275 → ₹285) via Stockpro Online; CHOLAFIN (₹1,835 → ₹1,850) via Sislofficial.
Short-term calls are designed to play out over two to four weeks. Quarterly results, FII flows, and sector rotation remain key variables during the holding period.
All recommendations reproduced here originate exclusively from SEBI-registered Research Analysts and are published for informational purposes only. These are not buy or sell recommendations from this publication. Registration with SEBI does not guarantee returns. Investing in securities markets is subject to market risks — read all related documents carefully before investing.
Disclaimer
All recommendations published on Bharatstox are sourced exclusively from SEBI-registered Research Analysts. Registration with SEBI does not guarantee returns or the performance of the intermediary. Investing in securities markets is subject to market risks. Read all related documents carefully before investing. This article is for informational purposes only and does not constitute investment advice.